plavix has been researched along with maraviroc in 1 studies
| Studies (plavix) | Trials (plavix) | Recent Studies (post-2010) (plavix) | Studies (maraviroc) | Trials (maraviroc) | Recent Studies (post-2010) (maraviroc) |
|---|---|---|---|---|---|
| 7 | 0 | 5 | 785 | 124 | 539 |
| Protein | Taxonomy | plavix (IC50) | maraviroc (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.1 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0014 | |
| C-C chemokine receptor type 5 | Homo sapiens (human) | 0.0044 | |
| C-C chemokine receptor type 5 | Mus musculus (house mouse) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for plavix and maraviroc
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |